Of the 4,582 adult subjects remaining after applying the exclusion criteria, 436 had unexplained ALT elevation (i.e., suspected NAFLD), which corresponds to 10.6% of the U.S. adult population or 19.4 million people (after accounting for NHANES sampling weights). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.